With 1.43 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.97 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $5.7 whereas the lowest price it dropped to was $5.18. The 52-week range on SGMT shows that it touched its highest point at $7.38 and its lowest point at $1.73 during that stretch. It currently has a 1-year price target of $28.00. Beta for the stock currently stands at 2.30.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of SGMT was up-trending over the past week, with a rise of 52.72%, but this was up by 66.56% over a month. Three-month performance surged to 50.56% while six-month performance rose 1.52%. The stock gained 14.87% in the past year, while it has gained 18.44% so far this year. A look at the trailing 12-month EPS for SGMT yields -1.78 with Next year EPS estimates of -3.08. For the next quarter, that number is -0.59. This implies an EPS growth rate of -74.49% for this year and -21.88% for next year.
Float and Shares Shorts:
At present, 30.67 million SGMT shares are outstanding with a float of 23.62 million shares on hand for trading. On 2025-05-15, short shares totaled 3.59 million, which was 1114.0 higher than short shares on 1744675200. In addition to Mr. David A. Happel as the firm’s CEO, President & Director, Mr. Thierry Chauche serves as its CFO & Principal Accounting Officer.
Institutional Ownership:
Through their ownership of 0.45821 of SGMT’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2025-03-31, SGMT reported revenue of $0.0 and operating income of -$19865000.0. The EBITDA in the recently reported quarter was -$19865000.0 and diluted EPS was -$0.56.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for SGMT since 5 analysts follow the stock currently. There are 4 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 1 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With SGMT analysts setting a high price target of 67.0 and a low target of 5.0, the average target price over the next 12 months is 27.42857. Based on these targets, SGMT could surge 1157.04% to reach the target high and fall by -6.19% to reach the target low. Reaching the average price target will result in a growth of 414.61% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$1.49935 being high and -$1.73301 being low. For SGMT, this leads to a yearly average estimate of -$1.5675. Based on analyst estimates, the high estimate for the next quarter is -$0.25 and the low estimate is -$0.94. The average estimate for the next quarter is thus -$0.57.
